OSE Immunotherapeutics announces H1 2021 results and provides a corporate update
22 September 2021Positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) after ICI failure. Positive Phase 1 dose... View Article
Naobios manufactures FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
Naobios today announces the next phase in its partnership with FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious... View Article
CLEAN CELLS INVESTS OVER €13M IN A NEW BIOPHARMACEUTICAL PRODUCTION SITE
15 September 20215,300 m2 new facility will quadruple analysis and production capacity, becoming largest site in Europe for biopharmaceuticals quality control services... View Article